Survey period for the second phase of REUMAVID finally concluded

The second survey of the REUMAVID project was closed on 22 April. A total of 2,002 responses were registered in this second phase (975 from UK, 308 from Spain, 218 from Italy, 181 from France, 159 from Portugal, 121 from Greece and 23 from Cyprus), 200 more than in the previous phase. This has only been possible thanks to the efforts of patient organizations disseminating the survey throughout Europe. We would like to thank all patients who agreed to participate in the REUMAVID project. The most frequent diseases in this second REUMAVID survey were Rheumatoid Arthritis (53.1%), Ankylosing Spondylitis/Axial Spondyloarthritis (24.4%) Osteoarthritis (23.0%) and Fibromyalgia (17.8%).

This second survey covers up-to-date topics, such as concerns about vaccination and the lasting working impact of the pandemic. In the coming weeks, the research team will work hard to conduct the necessary analyses to compare the current situation with that of the beginning of the COVID-19 pandemic. 

Stay tuned for further updates. 

REUMAVID is a project conducted by the Health & Territory Research (HTR) group of the University of Seville (Spain)

Supported by

Privacy Policy

© 2021 All Rights Reserved

Centro de preferencias de privacidad





      This website uses its own and third-party cookies to analyze and improve your browsing experience. By continuing to browse, we understand that you accept their use.    More information